S1PR3 and secondary progressive multiple sclerosis: Fingolimod, a modulator of S1PR1, S1PR3, S1PR4 subtypes, has been approved for the therapy of RRMS, whereas the more selective S1PR1 and S1PR5 modulator siponimod is an approved treatment for active SPMS.